Expert NetworkExpert InterviewSWTX

Slingshot members are talking to an expert! The topic is:

Discussing Mirdametinib, an investigational MEK inhibitor, in neurofibromatosis type 1 (NF1), and how it compares to selumetinib

Executed on:Feb 15, 2024 2:00 PM EDT
Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert
Institution: Mayo Clinic
  • Consultant, Department of Medical Genetics & Director of NF1 clinic at Mayo.
  • Research involves several collaborative basic research studies in the field of neurofibromatosis, in conjunction with Mayo's Neuro-Oncology Program and departments of Radiology and Neurologic Surgery.
  • Holds a leadership role in collaborative studies looking at children, adolescents and young adults with neurofibromatosis 1 and progressive plexiform neurofibromas as well as adult patients with neurofibromatosis 1 and extensive plexiform and paraspinal neurofibromas.

Interview Goal

Discuss how mirdametinib might stand out versus Koselugo 

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.